163 related articles for article (PubMed ID: 33970739)
1. Immune to addiction: how immunotherapies can be used to combat methamphetamine addiction.
Hossain MK; Hassanzadeganroudsari M; Kypreos E; Feehan J; Apostolopoulos V
Expert Rev Vaccines; 2021 Jun; 20(6):707-715. PubMed ID: 33970739
[No Abstract] [Full Text] [Related]
2. Vaccine development against methamphetamine drug addiction.
Hossain MK; Hassanzadeganroudsari M; Nurgali K; Apostolopoulos V
Expert Rev Vaccines; 2020 Dec; 19(12):1105-1114. PubMed ID: 33251859
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction.
Owens SM; Atchley WT; Hambuchen MD; Peterson EC; Gentry WB
CNS Neurol Disord Drug Targets; 2011 Dec; 10(8):892-8. PubMed ID: 22229314
[TBL] [Abstract][Full Text] [Related]
4. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse.
Carroll FI; Abraham P; Gong PK; Pidaparthi RR; Blough BE; Che Y; Hampton A; Gunnell M; Lay JO; Peterson EC; Owens SM
J Med Chem; 2009 Nov; 52(22):7301-9. PubMed ID: 19877685
[TBL] [Abstract][Full Text] [Related]
5. Development of active and passive human vaccines to treat methamphetamine addiction.
Gentry WB; Rüedi-Bettschen D; Owens SM
Hum Vaccin; 2009 Apr; 5(4):206-13. PubMed ID: 19276653
[TBL] [Abstract][Full Text] [Related]
6. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse.
Peterson EC; Gunnell M; Che Y; Goforth RL; Carroll FI; Henry R; Liu H; Owens SM
J Pharmacol Exp Ther; 2007 Jul; 322(1):30-9. PubMed ID: 17452421
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of a novel conjugated methamphetamine vaccine.
Kamal Hossain M; Davidson M; Feehan J; Deraos G; Nurgali K; Matsoukas J; Apostolopoulos V
Vaccine; 2022 Sep; 40(41):5882-5891. PubMed ID: 36041942
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.
Laurenzana EM; Stevens MW; Frank JC; Hambuchen MD; Hendrickson HP; White SJ; Williams DK; Owens SM; Gentry WB
Hum Vaccin Immunother; 2014; 10(9):2638-47. PubMed ID: 25483484
[TBL] [Abstract][Full Text] [Related]
9. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period.
Hambuchen MD; Rüedi-Bettschen D; Williams DK; Hendrickson H; Owens SM
Vaccine; 2014 Oct; 32(47):6213-9. PubMed ID: 25252196
[TBL] [Abstract][Full Text] [Related]
10. Structural characterization of a therapeutic anti-methamphetamine antibody fragment: oligomerization and binding of active metabolites.
Peterson EC; Celikel R; Gokulan K; Varughese KI
PLoS One; 2013; 8(12):e82690. PubMed ID: 24349338
[TBL] [Abstract][Full Text] [Related]
11. Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction.
Gentry WB; Rüedi-Bettschen D; Owens SM
Clin Pharmacol Ther; 2010 Sep; 88(3):390-3. PubMed ID: 20668443
[TBL] [Abstract][Full Text] [Related]
12. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response.
Hambuchen MD; Carroll FI; Rüedi-Bettschen D; Hendrickson HP; Hennings LJ; Blough BE; Brieaddy LE; Pidaparthi RR; Owens SM
J Med Chem; 2015 Jun; 58(11):4665-77. PubMed ID: 25973614
[TBL] [Abstract][Full Text] [Related]
13. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
Stevens MW; Tawney RL; West CM; Kight AD; Henry RL; Owens SM; Gentry WB
MAbs; 2014; 6(2):547-55. PubMed ID: 24492290
[TBL] [Abstract][Full Text] [Related]
14. Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.
Peterson EC; Gentry WB; Owens SM
Adv Pharmacol; 2014; 69():107-27. PubMed ID: 24484976
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for treating methamphetamine, heroin and cocaine use disorders.
Xiaoshan T; Junjie Y; Wenqing W; Yunong Z; Jiaping L; Shanshan L; Kutty Selva N; Kui C
Drug Discov Today; 2020 Mar; 25(3):610-619. PubMed ID: 31419495
[TBL] [Abstract][Full Text] [Related]
16. Methamphetamine: Mechanism of Action and Chinese Herbal Medicine Treatment for Its Addiction.
Zeng R; Pu HY; Zhang XY; Yao ML; Sun Q
Chin J Integr Med; 2023 Jul; 29(7):665-672. PubMed ID: 37074617
[TBL] [Abstract][Full Text] [Related]
17. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats.
Laurenzana EM; Byrnes-Blake KA; Milesi-Hallé A; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2003 Nov; 31(11):1320-6. PubMed ID: 14570763
[TBL] [Abstract][Full Text] [Related]
18. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food.
Rüedi-Bettschen D; Wood SL; Gunnell MG; West CM; Pidaparthi RR; Carroll FI; Blough BE; Owens SM
Vaccine; 2013 Sep; 31(41):4596-602. PubMed ID: 23906885
[TBL] [Abstract][Full Text] [Related]
19. The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats.
Harris AC; LeSage MG; Shelley D; Perry JL; Pentel PR; Owens SM
PLoS One; 2015; 10(3):e0118787. PubMed ID: 25742165
[TBL] [Abstract][Full Text] [Related]
20. Development of Methamphetamine Conjugated Vaccine through Hapten Design: In Vitro and In Vivo Characterization.
Hossain MK; Davidson M; Feehan J; Deraos G; Nurgali K; Matsoukas J; Apostolopoulos V
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]